✦ LIBER ✦

PCN37 Cost-Minimization Analysis of Second-Line Chemotherapy for Non-Small-Cell Lung Cancer (NSCLC)

✍ Scribed by Laurendeau, C.; Chouaid, C.; Florentin, V.; Duchon D'engenières, V.; Detournay, B.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Second line chemotherapy (CT) in advance

✍ Westeel, V.; Jacoulet, P.; Dubiez, A.; Polio, J.C.; Pemet, D.; Depierre, A. 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 253 KB

Second–line chemotherapy for non—small–c

✍ Frank V. Fossella 📂 Article 📅 2000 🏛 Current Science Inc. 🌐 English ⚖ 225 KB

PCN69 HEALTH UTILITIES IN THE UK FOR SEC

✍ B Nafees; MR Stafford; S Bhalla; J Watkins 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB

PCN9 ERLOTINIB IN NON-SMALL CELL LUNG CA

✍ A Gabriel; O Pirk; W Kotowa 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

PCN6: MODELLING THE COST-EFFECTIVENESS O

✍ P Sharplin; UK Bose; J Holmes 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 52 KB

PCN37 Cost Comparison of Erlotinib Versu

✍ Schwander, B.; Ravera, S.; Giuliani, G.; Nuijten, M.; Walzer, S. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB